RS60003B1 - Formulacije polipeptida faktora viii - Google Patents

Formulacije polipeptida faktora viii

Info

Publication number
RS60003B1
RS60003B1 RS20200243A RSP20200243A RS60003B1 RS 60003 B1 RS60003 B1 RS 60003B1 RS 20200243 A RS20200243 A RS 20200243A RS P20200243 A RSP20200243 A RS P20200243A RS 60003 B1 RS60003 B1 RS 60003B1
Authority
RS
Serbia
Prior art keywords
polysorbate
rfviiifc
pharmaceutical composition
polypeptide
factor viii
Prior art date
Application number
RS20200243A
Other languages
English (en)
Serbian (sr)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of RS60003B1 publication Critical patent/RS60003B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20200243A 2013-03-15 2014-03-14 Formulacije polipeptida faktora viii RS60003B1 (sr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30
EP14725816.4A EP2968477B1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations
PCT/US2014/029354 WO2014144795A1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Publications (1)

Publication Number Publication Date
RS60003B1 true RS60003B1 (sr) 2020-04-30

Family

ID=50771579

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200243A RS60003B1 (sr) 2013-03-15 2014-03-14 Formulacije polipeptida faktora viii

Country Status (20)

Country Link
US (4) US9623088B2 (enExample)
EP (3) EP2968477B1 (enExample)
JP (5) JP6330026B2 (enExample)
AU (4) AU2014228506A1 (enExample)
CA (1) CA2899737A1 (enExample)
CL (1) CL2015002720A1 (enExample)
DK (1) DK2968477T3 (enExample)
EA (2) EA030357B1 (enExample)
ES (2) ES2926798T3 (enExample)
HU (1) HUE047933T2 (enExample)
LT (1) LT2968477T (enExample)
PH (2) PH12015501801B1 (enExample)
PL (2) PL3666283T3 (enExample)
PT (2) PT3666283T (enExample)
RS (1) RS60003B1 (enExample)
SG (2) SG11201505924TA (enExample)
SI (1) SI2968477T1 (enExample)
TW (2) TWI629993B (enExample)
UY (1) UY35462A (enExample)
WO (1) WO2014144795A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4382170A3 (en) * 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
EP3706720B1 (en) 2017-11-07 2026-07-01 Rani Therapeutics, LLC COAGULATION FACTOR PREPARATIONS FOR ADMINISTERING INTO INTESTINAL TRACT TISSUE BY MEANS OF AN ORGIVE-IN-SWALLOW MEDICATION DELIVERY DEVICE
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
EP3870206A4 (en) * 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION
JP7501875B2 (ja) * 2019-02-28 2024-06-18 公立大学法人横浜市立大学 血液凝固および／または補体異常疾患の治療用組成物
WO2020215010A1 (en) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物
CN119173254A (zh) * 2022-05-10 2024-12-20 株式会社绿十字 血浆蛋白的新型液体制剂

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE122010000006I2 (de) 1989-02-21 2012-06-21 Univ Washington Modifizierte formen von fortpflanzungshormonen.
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ES2427627T3 (es) 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP4169525A1 (en) * 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
CN103917554B (zh) * 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
JP2015527350A (ja) 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子の液体製剤
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII

Also Published As

Publication number Publication date
PH12019502452A1 (en) 2021-02-08
US20210069300A1 (en) 2021-03-11
CL2015002720A1 (es) 2016-11-04
JP6330026B2 (ja) 2018-05-23
CA2899737A1 (en) 2014-09-18
PT2968477T (pt) 2020-03-11
AU2021277601B2 (en) 2025-03-06
US9623088B2 (en) 2017-04-18
JP7700164B2 (ja) 2025-06-30
TW201501722A (zh) 2015-01-16
SG10201805207QA (en) 2018-07-30
JP2020186268A (ja) 2020-11-19
US12403183B2 (en) 2025-09-02
TWI629993B (zh) 2018-07-21
PH12015501801B1 (en) 2019-11-20
EP2968477B1 (en) 2019-12-04
AU2014228506A1 (en) 2015-08-13
TW201842930A (zh) 2018-12-16
ES2776195T3 (es) 2020-07-29
TWI690325B (zh) 2020-04-11
EA201890671A1 (ru) 2019-01-31
AU2025204069A9 (en) 2026-03-19
SG11201505924TA (en) 2015-09-29
EP2968477A1 (en) 2016-01-20
EP4122487A1 (en) 2023-01-25
JP2021181491A (ja) 2021-11-25
HUE047933T2 (hu) 2020-05-28
JP2023060146A (ja) 2023-04-27
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
PL3666283T3 (pl) 2022-10-03
JP2016516722A (ja) 2016-06-09
JP2018123161A (ja) 2018-08-09
WO2014144795A1 (en) 2014-09-18
PL2968477T3 (pl) 2020-06-15
AU2021277601A1 (en) 2021-12-23
US20140308280A1 (en) 2014-10-16
JP6934994B2 (ja) 2021-09-15
PH12015501801A1 (en) 2015-11-09
EP3666283B1 (en) 2022-06-08
DK2968477T3 (da) 2020-03-09
UY35462A (es) 2014-10-31
US20260137760A1 (en) 2026-05-21
EA030357B1 (ru) 2018-07-31
EA201591439A1 (ru) 2016-03-31
PT3666283T (pt) 2022-09-13
HK1220617A1 (en) 2017-05-12
JP7240457B2 (ja) 2023-03-15
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
US10786554B2 (en) 2020-09-29
LT2968477T (lt) 2020-03-10
AU2025204069A1 (en) 2025-06-26
ES2926798T3 (es) 2022-10-28
EP3666283A1 (en) 2020-06-17

Similar Documents

Publication Publication Date Title
JP7700164B2 (ja) 第ｖｉｉｉ因子ポリペプチド製剤
JP7636481B2 (ja) 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
EP2908847B1 (en) Methods of using a fixed dose of a clotting factor
HK40087935A (en) Factor viii polypeptide formulations
HK1220617B (en) Factor viii polypeptide formulations
HK40032761A (en) Factor viii polypeptide formulations
HK40032761B (en) Factor viii polypeptide formulations
HK40091851A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK40011493A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK40011493B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK1197805B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK1197805A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof